BRAF and neoplasm: The profile of reactivating mechanisms varies relative to BRAF monotherapy versus combination BRAF and MEK targeted therapy, whereby BRAF splice variants are common in BRAF inhibitor resistance, MEK2 mutations are common in combination-resistant tumours, whilst NRAS mutations are common to both single agent and combination therapies [41].